SCHEMBL23367256

SCHEMBL23367256

CCOC(=O)/C(C=O)=N/Nc1ccc(F)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.44
NPSR1 Q6W5P4 3/20 0.44
TLR4 O00206 4/20 0.42
GAA P10253 6/20 0.42
TP53 P04637 1/20 0.42
ABCB1 P08183 1/20 0.41
LMNA P02545 4/20 0.40
NPC1 O15118 1/20 0.40
ATM Q13315 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
ALDH1A1 P00352 1/20 0.39
THRB P10828 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29874328 0.94 MAPT (0.40) MAPTNPSR1TLR4GAATP53
SCHEMBL23367422 0.89 MAPT (0.47) MAPTNPSR1GAALMNANPC1
SCHEMBL29874296 0.89 MAPT (0.47) MAPTNPSR1GAALMNANPC1
SCHEMBL25415902 0.89 MAPT (0.47) MAPTNPSR1GAALMNANPC1
SCHEMBL23385014 0.88 MAPT (0.43) MAPTNPSR1TLR4GAATP53
SCHEMBL29873902 0.88 MAPT (0.49) MAPTGAATP53ABCB1LMNA
SCHEMBL23367287 0.88 MAPT (0.49) MAPTGAATP53ABCB1LMNA
SCHEMBL29873916 0.85 MAPT (0.43) MAPTNPSR1GAAABCB1LMNA
SCHEMBL23367405 0.85 MAPT (0.43) MAPTNPSR1GAAABCB1LMNA
SCHEMBL1779128 0.85 MAPT (0.47) MAPTNPSR1TLR4GAATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-4058446-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed
WO-2021094434-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2021-05-20 WO disclosed
EP-3822265-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer AG (DE) 2021-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAMTS1 MAPT 4378/4885NPSR1 111/4885TLR4 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.